High hypoxia inducible factor-1α expression is associated with reduced survival in patients with breast cancer: A meta-analysis.

IF 3.2 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-06-24 DOI:10.5306/wjco.v16.i6.105691

Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu

{"title":"High hypoxia inducible factor-1α expression is associated with reduced survival in patients with breast cancer: A meta-analysis.","authors":"Xue-Di Zheng, Huan-Yu Li, Si-Yu Gao, Qi Wang, Jiang-Bo Liu","doi":"10.5306/wjco.v16.i6.105691","DOIUrl":null,"url":null,"abstract":"Background: Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.Aim: To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.Methods: A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.Results: This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (P = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.Conclusion: Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"105691"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198862/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.105691","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hypoxia-inducible factor 1α (HIF-1α) plays a crucial role in the prognosis of breast cancer, but the current evidence remains inconclusive.

Aim: To provide comprehensive evidence about the correlation of altered HIF-1α expression with overall survival (OS) and disease-free survival (DFS) in breast cancer patients.

Methods: A systematic search was conducted in PubMed, Embase, and Web of Science databases to collect relevant articles that were published before April 8, 2024. A meta-analysis was used to assess the impact of altered HIF-1α expression on the OS and DFS of breast cancer patients. Subgroup and sensitivity analyses were also performed in this meta-analysis.

Results: This meta-analysis included 40 studies. The average percentage of breast cancer patients with high HIF-1α expression was 39.6%. The overall meta-analysis results demonstrated that high HIF-1α expression is strongly linked to poor outcomes in patients of breast cancer. Compared with low HIF-1α expression, the overall hazard ratio for OS in patients with high HIF-1α expression was 1.47 [95% confidence interval (CI): 1.29-1.69], and the overall hazard ratio for DFS was 1.82 (95%CI: 1.56-2.12). Furthermore, both OS [1.18 (95%CI: 1.01-1.38)] and DFS [1.79 (95%CI: 1.03-3.11)] were markedly shorter in triple-negative breast cancer cases with high HIF-1α expression. Subgroup analysis revealed that the antibody used to detect HIF-1α expression affected only the correlation linking HIF-1α expression to DFS in breast cancer patients (P = 0.0004). Furthermore, the sensitivity analysis demonstrates that the overall conclusions of the meta-analysis were unaffected by the removal of individual studies.

Conclusion: Compared to patients with low HIF-1α expression, those with high expression level had shorter OS and DFS. However, the prognostic significance of high HIF-1α expression varies across molecularly stratified breast cancer cohorts needs to be further elucidated.

Abstract Image

查看原文本刊更多论文

低氧诱导因子-1α高表达与乳腺癌患者生存率降低相关：一项荟萃分析

背景：低氧诱导因子1α (HIF-1α)在乳腺癌预后中起着至关重要的作用，但目前尚无确切证据。目的：为乳腺癌患者HIF-1α表达改变与总生存期（OS）和无病生存期（DFS）的相关性提供综合证据。方法：系统检索PubMed、Embase和Web of Science数据库，收集2024年4月8日之前发表的相关文章。采用荟萃分析评估HIF-1α表达改变对乳腺癌患者OS和DFS的影响。本荟萃分析还进行了亚组分析和敏感性分析。结果：本荟萃分析包括40项研究。HIF-1α高表达乳腺癌患者的平均比例为39.6%。整体荟萃分析结果表明，高HIF-1α表达与乳腺癌患者的不良预后密切相关。与HIF-1α低表达患者相比，HIF-1α高表达患者发生OS的总风险比为1.47[95%可信区间（CI）： 1.29-1.69]，发生DFS的总风险比为1.82 （95%CI: 1.56-2.12）。此外，HIF-1α高表达的三阴性乳腺癌患者的OS [1.18 (95%CI: 1.01-1.38)]和DFS [1.79 (95%CI: 1.03-3.11)]均明显较短。亚组分析显示，用于检测HIF-1α表达的抗体仅影响乳腺癌患者HIF-1α表达与DFS的相关性（P = 0.0004）。此外，敏感性分析表明，meta分析的总体结论不受个别研究删除的影响。结论：与HIF-1α低表达患者相比，HIF-1α高表达患者的OS和DFS均较短。然而，HIF-1α高表达在不同分子分层乳腺癌队列中的预后意义有待进一步阐明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.